Information Provided By: 
Fly News Breaks for March 28, 2019
AMRN
Mar 28, 2019 | 08:57 EDT
The American Diabetes Association updated its treatment guidelines to include Amarin's Vascepa for patients with diabetes and cardiovascular disease, Jefferies analyst Michael Yee tells investors in a research note. The analyst views the addition as an incremental positive that should help drive Vascepa sales in 2019. Further, Q1 scripts suggest Vascepa sales of $80M-$85M, above the consensus estimate of $67M, Yee says. He keeps a Buy rating on Amarin with a $30 price target.
News For AMRN From the Last 2 Days
There are no results for your query AMRN
